Industion chemotherapy plus late-course hyperfractionation accelerated radiotherapy in locally advanced non-small cell lung cancer: stage Ⅰ + Ⅱ clinical results

Ming CHEN,Yuan-yuan CHEN,Chao-gui XIAN,Guo-zhen LIU,Shao-xiong WU,Nian-Ji CUI

DOI: https://doi.org/10.3760/j.issn:1004-4221.2005.04.004

2005-01-01

Abstract:Objective Objective To study the toxicities and efficacy of induction chemotherapy plus late-course hyperfractionation accelerated radiotherapy (LCHART) in unresectable locally advanced non-small cell lung (NSCLC)cancer. Methods From 1998 to 2000 years, 58 unresectable stage ⅢA(N2)～ⅢB NSCLC patients eligible for this study, received 2-4cycles of cisplatin-based chemotherapy followed by first conventional fractionation radiotherapy (2?Gy/f, 1f/d,totally 40?Gy)with AP-PA large fields encompassing the primary tumor, positive lymph nodes and elective lymph node region, then by LCHART(1.5?Gy/f, 2f/d, totally 27?Gy) with cone-down fields covering the primary tumor. Results Totally 53 patients were eligible for analysis. The response rate was 58.5% when evaluated by enhancement CT scans 1 month after completion of radiotherapy. The 1-,2-,3-and 4-year overall survivals were 59.3%、22.8%、13.7%、11.4%,respectively. The 1-,2-,3-and 4-year locally disease-free survivals were 43.6%、22.9%、12.9%、8.6%, respectively. Twelve patients developed grade Ⅲ and 3 grade IV granulocytopenia, 14 grade Ⅱ and 2 grade Ⅲ radiation esophagitis, 9 grade Ⅱ and 1 grade Ⅲ radiation pneumonitis. 59.5% of patients developed distant metastasis in those had shown no response to induction chemotherapy, whereas only 18.8% did in those had shown positive response to induction chemotherapy (P= 0.006 ). Conclusions The toxicity of induction chemotherapy plus late-course hyperfractionation accelerated radiotherapy in locally advanced non-small cell lung cancer is tolerable. The mean survival time is longer in induction chemotherapy plus late course hyperfractionation accelerated radiotherapy than it is in induction chemotherapy plus conventional radiotherapy. Progression of intra-thoracic primary tumor is the main lethal cause.